Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques

2008/04/15 by Jian Yan, Kristina A. Harris, Kristina Harris +7 · 28 citations
Medicine · Immunology and Microbiology · #Cervical Cancer and HPV Research #Immunotherapy and Immune Responses #Hepatitis B Virus Studies

paper · doi:10.1016/j.vaccine.2008.03.069

Cited by

• Synergy Effects of HPV E6‐E7 Encoding mRNA and Nucleic Acid Immunostimulators Improve Therapeutic Potential in TC‐1 Graft Tumor
• mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization
• Development of HPV nanovaccine candidate based on IL-15-E7 fusion protein encapsulated in silk-fibroin nanoparticles
• Therapeutic HPV DNA vaccines. [europepmc]
• Therapeutic HPV DNA vaccines. [europepmc]
• Immunotherapy for cervical cancer: Research status and clinical potential. [europepmc]
• Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. [europepmc]
• Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. [europepmc]
• Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen. [europepmc]
• Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. [europepmc]
• Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. [europepmc]
• Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. [europepmc]
• Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. [europepmc]
• A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). [europepmc]
• Current state in the development of candidate therapeutic HPV vaccines. [europepmc]
• Perspectives for therapeutic HPV vaccine development. [europepmc]
• The current state of therapeutic and T cell-based vaccines against human papillomaviruses. [europepmc]
• Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. [europepmc]
• Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. [europepmc]
• Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. [europepmc]
• A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. [europepmc]
• Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses. [europepmc]
• Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8 + T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. [europepmc]
• Advances in gene-based vaccine platforms to address the COVID-19 pandemic. [europepmc]
• Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials. [europepmc]
• Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy. [europepmc]
• Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). [europepmc]
• A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. [europepmc]